News
VXRT
1.300
+0.78%
0.010
Weekly Report: what happened at VXRT last week (0318-0322)?
Weekly Report · 3d ago
Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to the Company's new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines.
Dow Jones · 03/20 12:00
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Vaxart (VXRT) with a price target of $2.00. The company's lead norovirus vaccine candidate is nearing the end of Phase II trials with promising immunogenicity and efficacy data.
TipRanks · 03/20 11:25
Weekly Report: what happened at VXRT last week (0311-0315)?
Weekly Report · 03/18 10:05
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
Vaxart reported earnings per share of -12 cents for the fourth quarter of 2023. The company reported revenue of $3.25 million. This was 159.60% better than the analyst estimate for revenue. Vaxart also reported results for the third quarter of 2018.
Investorplace · 03/15 00:55
Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M
Earnings News Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
Seeking Alpha · 03/14 20:15
Options Volatility and Implied Earnings Moves Today, March 14, 2024
Several major companies are expected to report earnings today. Adobe (ADBE), Dollar General (DG) and Weibo (WB) are among the companies. TipRanks shows you the expected earnings move, based on options prices. The list is divided by the timing of each company's earnings release.
TipRanks · 03/14 12:05
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Adobe, Ulta Beauty, Skillz and Wheaton Precious Metals Corp. Other notable earnings slated for release after Thursday's close include: ZUMZ, ULTA and Blink Charging Co. Other companies with major earnings scheduled after the close of business on Thursday.
Seeking Alpha · 03/13 21:35
Vaxart FY 2023 Earnings Preview
Vaxart (NASDAQ:VXRT) is scheduled to announce FY earnings results on Thursday, March 14th. The consensus EPS Estimate is -$0.61 and the consensus revenue estimate is $5.21M. Over the last 2 years, VXRT has beaten estimates 38% of the time.
Seeking Alpha · 03/13 21:35
Vaxart's Earnings: A Preview
Vaxart is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.14. Last quarter the company beat EPS by $0.07. Shares of Vaxart were trading at $1.14 as of March 12.
Benzinga · 03/13 19:01
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
NASDAQ · 03/11 12:03
Options Volatility and Implied Earnings Moves This Week, March 11 – March 15, 2024
TipRanks · 03/11 12:00
Weekly Report: what happened at VXRT last week (0304-0308)?
Weekly Report · 03/11 10:03
Vaxart appoints Steven Lo as president, CEO, and director
Healthcare Vaxart appoints Steven Lo as president, CEO, and director. Lo was most recently with Valitor, a private biotech company. VXRT is -1.65% to $1.19 in after-hours trading on the New York Stock Exchange.
Seeking Alpha · 03/06 17:28
Vaxart Inc Welcomes Steven Lo as New CEO and President
TipRanks · 03/06 14:32
Vaxart Names Steven Lo President, Chief Executive
Biotechnology company Vaxart has hired veteran biopharma executive Steven Lo as president and chief executive. Lo has more than 25 years of experience in the healthcare, biotechnology and pharmaceutical industries. He will join the board effective March 18. Michael Finney, interim CEO, will continue as chairman of the company.
Dow Jones · 03/06 13:17
Vaxart Appoints Steven Lo As President And CEO
Benzinga · 03/06 13:11
Press Release: Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director Michael J. Finney, Ph.D. To Continue as Chairman of the Board of Directors. Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience.
Dow Jones · 03/06 13:00
Weekly Report: what happened at VXRT last week (0226-0301)?
Weekly Report · 03/04 10:05
More
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about Vaxart Inc through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.